Avenue Therapeutics, Inc.(ATXI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATXI Avenue Therapeutics, Inc.

Trading 05-14 10:08:50 EDT Delay

{"stockData":{"symbol":"ATXI","market":"US","secType":"STK","nameCN":"Avenue Therapeutics, Inc.","latestPrice":0.4015,"timestamp":1778767730224,"preClose":0.4015,"halted":0,"volume":59,"delay":15,"changeRate":0,"floatShares":1496100,"shares":2053899,"eps":-0.547589,"marketStatus":"Trading","change":0,"latestTime":"05-14 10:08:50 EDT Delay","open":0.4015,"high":0.4015,"low":0.4015,"amount":20.065,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.547589,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778788800000},"marketStatusCode":2,"adr":0,"exchange":"PINK","adjPreClose":0.4015,"volumeRatio":0.104052},"requestUrl":"/m/hq/s/ATXI/","defaultTab":"news","newsList":[{"id":"2633567774","title":"Avenue Therapeutics Q1 net loss narrows to $695,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2633567774","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633567774?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:34","pubTimestamp":1778243645,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics posted a net loss of $695,000, or $0.21 per share, for the quarter ended March 31, 2026.Operating loss narrowed to $714,000 as operating expenses fell to $714,000, reflecting research and development expense of $200,000 and general and administrative expense of $514,000.Cash and cash equivalents declined to $2.42 million, with net cash used in operating activities of $438,000.Company highlighted February 2026 exclusive worldwide license from Duke University for ATX-04  in Pompe disease, with upfront payments totaling about $19,000 and milestone obligations totaling about $15.6 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDLbP3d4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","FBIO","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623100324","title":"Avenue Therapeutics FY25 net loss narrows 75% to $2.9 million; revenue hits $1.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623100324","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623100324?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:45","pubTimestamp":1774907157,"startTime":"0","endTime":"0","summary":"Revenue reached $1.4 million, driven by payments from AnnJi tied to termination of the AJ201 license.Cash and cash equivalents totaled $2.9 million at Dec. 31, 2025.Pipeline focus shifted to ATX-04 ahead of a planned FDA pre-IND meeting, while IV tramadol Phase 3 safety study remains subject to financing or a partnership; without additional capital, cash is not expected to fund operating requirements for more than 12 months from issuance of the financial statements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Marc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2nhsF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","BK4007","FBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613978283","title":"Avenue Therapeutics licenses ATX-04 worldwide for Pompe disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2613978283","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613978283?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:05","pubTimestamp":1771851900,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics, founded by Fortress Biotech Inc., entered into an exclusive worldwide license agreement with Duke University for ATX-04  to treat Pompe disease. Avenue said it will advance ATX-04 as an adjunct to enzyme replacement therapy and will assume control of Duke’s existing clinical and regulatory assets for the program, including the IND and FDA orphan drug designation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL7W3BPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATXI","FBIO","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613784273","title":"Avenue Therapeutics Enters Into Exclusive Worldwide License Agreement for Atx-04 for the Treatment of Pompe Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2613784273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613784273?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUAPSRCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","FBIO","ATXI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595377782","title":"Avenue Therapeutics Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2595377782","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595377782?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:21","pubTimestamp":1767190895,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics Inc. held its annual meeting of stockholders on December 30, 2025. Shareholders approved the election of six directors and ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the year ending December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL2D8GDz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FBIO","ATXI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589817759","title":"Avenue Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589817759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589817759?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:02","pubTimestamp":1764968577,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics Inc. has announced that its Annual Meeting of Stockholders will be held virtually on December 30, 2025. During the meeting, stockholders will be asked to vote on the election of six directors for a one-year term and to ratify the appointment of KPMG LLP as the company's independent registered public accounting firm for the year ending December 31, 2025. The meeting may also address any other business that is properly presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8l9NR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FBIO","ATXI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582730379","title":"Axsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2582730379","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582730379?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:03","pubTimestamp":1762952581,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics' majority-owned subsidiary, Baergic Bio, is being acquired by Axsome Therapeutics, which will receive global rights to BAER-101 , a novel oral GABAA α2,3 receptor modulator. Under the terms of the agreement, Baergic Bio shareholders are set to receive a $0.3 million upfront payment , with eligibility for milestone payments of up to $2.5 million for the first indication and $1.5 million for each additional indication. The deal also includes up to $79 million in potential sales-based milestones and a tiered mid-to-high single-digit royalty on global net sales of AXS-17. Avenue is expected to receive approximately 74% of all future payments and royalties under the agreement. Axsome plans to advance AXS-17 in epilepsy, leveraging anti-convulsant effects observed in preclinical models.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6dDB3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4007","BK4585","FBIO","BK4139","ATXI","AXSM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avenuetx.com","description":"Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.","exchange":"PINK","name":"Avenue Therapeutics, Inc.","nameEN":"Avenue Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avenue Therapeutics, Inc.(ATXI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avenue Therapeutics, Inc.(ATXI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avenue Therapeutics, Inc.,ATXI,Avenue Therapeutics, Inc.股票,Avenue Therapeutics, Inc.股票老虎,Avenue Therapeutics, Inc.股票老虎国际,Avenue Therapeutics, Inc.行情,Avenue Therapeutics, Inc.股票行情,Avenue Therapeutics, Inc.股价,Avenue Therapeutics, Inc.股市,Avenue Therapeutics, Inc.股票价格,Avenue Therapeutics, Inc.股票交易,Avenue Therapeutics, Inc.股票购买,Avenue Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avenue Therapeutics, Inc.(ATXI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avenue Therapeutics, Inc.(ATXI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction